摘要
The approval of imatinib in 2001 has changed the landscape of CML management.^-3 With its excellent efficacy in the International Interferon and STI571 （IRIS）, Randomized Study of imatinib has become the standard of care for newly diagnosed patients. This change challenges the previous role of allogeneic hematopoietic stem cell transplantation （allo-HSCT） in CML treatment. However,
The approval of imatinib in 2001 has changed the landscape of CML management.^-3 With its excellent efficacy in the International Interferon and STI571 （IRIS）, Randomized Study of imatinib has become the standard of care for newly diagnosed patients. This change challenges the previous role of allogeneic hematopoietic stem cell transplantation （allo-HSCT） in CML treatment. However,
基金
This work was supported （in part） by the grants from the National Outstanding Young Scientist＇s Foundation of China （No. 30725038）, the National Natural Science Foundation of China （No. 30971292）, and the Leading Program of Clinical Faculty accredited by the Ministry of Health of China.
